Moreover, a separate study showed that inhibiting MAP4K7 kinase activity using small-molecule inhibitors is a promising therapeutic strategy in colorectal cancer, as it disrupts the interaction of MAP4K7 with TCF4 and β-catenin62. The gene discussed is TNIK; the disease is colorectal cancer.